Liraglutide impresses in Ph III trials
Danish insulin giant Novo Nordisk says that its investigational drug liraglutide, a once-daily human GLP-1 analog, improved glucose control and lowered body weight in diabetic patients during two Phase III clinical trials.
The studies, which form part of the LEAD evaluation program, ran for 26 weeks and were designed to assess the effect of liraglutide on diabetes symptoms at a range of doses. In LEAD-1, glimepride-treated patients were randomized to add either liraglutide, rosiglitazone or placebo to their therapeutic regimen, while the LEAD-2 trial assigned participants liraglutide, glimepride or placebo in addition to standard metformin therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze